Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Stock analysts at Brookline Capital Management decreased their FY2023 earnings per share (EPS) estimates for Adial Pharmaceuticals in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($5.46) per share for the year, down from […]